Cellectis SA (CLLS) Stock Analysis

Cellectis SA (CLLS) is a publicly traded company in the HEALTHCARE sector. It trades at $3.38, carries a market capitalization of $350.13M. This page summarizes the public market data, fundamentals, and frequently asked questions for CLLS, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $3.38
• Market Cap: $350.13M
• EPS: $-0.67
• 52-Week High: $5.48
• 52-Week Low: $1.33

Market Sentiment

Cellectis SA currently has a Bullish sentiment score of 0.51.

About Cellectis SA

Cellectis SA is a clinical-stage biotechnology firm headquartered in Paris, France, specializing in the development of innovative immuno-oncology therapies utilizing its proprietary gene-editing platform. By leveraging its cutting-edge technology, the company creates T cell therapies that incorporate chimeric antigen receptors (CARs) to effectively target and eliminate cancer cells. With a diverse pipeline of candidates at various clinical development stages and strategic partnerships, Cellec...

GNG Research Analysis

GNG Research scores Cellectis SA (CLLS) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for CLLS.

Frequently Asked Questions

Does CLLS pay dividends?

Cellectis SA (CLLS) does not currently pay a regular dividend.

What is CLLS's market cap?

Cellectis SA (CLLS) has a market capitalization of $350.13M with a current stock price of $3.38.